Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration- resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary.

Slides:

Advertisements

Similar presentations

Charles J. Ryan, M.D., Matthew R. Smith, M.D., Ph.D., Johann S. de Bono, M.B., Ch.B., Ph.D., Arturo Molina, M.D., Christopher J. Logothetis, M.D., Paul.

Advertisements

Volume 69, Issue 5, Pages (May 2016)

The PSA Era is not Over for Prostate Cancer

Volume 50, Issue 1, Pages (July 2006)

Volume 52, Issue 1, Pages (July 2007)

Volume 60, Issue 2, Pages (August 2011)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono

Volume 69, Issue 5, Pages (May 2016)

Volume 56, Issue 6, Pages (December 2009)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 59, Issue 3, Pages (March 2011)

Volume 68, Issue 4, Pages (October 2015)

Volume 66, Issue 5, Pages (November 2014)

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.

Volume 53, Issue 5, Pages (May 2008)

Volume 69, Issue 5, Pages (May 2016)

Volume 51, Issue 4, Pages (April 2007)

Managing Nonmetastatic Castration-resistant Prostate Cancer

Volume 49, Issue 5, Pages (May 2006)

Prostate Cancer Epidemic in Sight?

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration- resistant Prostate Cancer in the Era of Precision Oncology Philipp.

Volume 70, Issue 5, Pages (November 2016)

Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer Olav Erich Yri, Trine Bjoro, Sophie D.

Volume 68, Issue 4, Pages (October 2015)

Volume 63, Issue 2, Pages (February 2013)

Volume 53, Issue 2, Pages (February 2008)

Volume 74, Issue 1, Pages (July 2018)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 67, Issue 2, Pages (February 2015)

Volume 70, Issue 4, Pages (October 2016)

Volume 53, Issue 4, Pages (April 2008)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 66, Issue 3, Pages (September 2014)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 66, Issue 5, Pages (November 2014)

Volume 70, Issue 5, Pages (November 2016)

Volume 69, Issue 6, Pages (June 2016)

Volume 73, Issue 6, Pages (June 2018)

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Volume 61, Issue 5, Pages (May 2012)

Volume 74, Issue 3, Pages (September 2018)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 73, Issue 3, Pages (March 2018)

Leonard S. Marks, Jiaoti Huang European Urology

Volume 72, Issue 1, Pages (July 2017)

Volume 66, Issue 2, Pages (August 2014)

Volume 74, Issue 2, Pages (August 2018)

Volume 67, Issue 1, Pages (January 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 71, Issue 2, Pages (February 2017)

Volume 48, Issue 6, Pages (December 2005)

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 67, Issue 6, Pages (June 2015)

Volume 66, Issue 5, Pages (November 2014)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 72, Issue 2, Pages (August 2017)

Volume 70, Issue 1, Pages (July 2016)

Volume 71, Issue 4, Pages (April 2017)

Volume 69, Issue 5, Pages (May 2016)

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Volume 68, Issue 5, Pages (November 2015)

European Urology Oncology

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

CONSORT diagram. a, 5 had a major treatment violation (3 refused and 2 received wrong treatment) but were included in the analyses; b, 4 had a major treatment.

Presentation transcript:

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration- resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint Ethan M. Basch, Mark Scholz, Johann S. de Bono, Nicholas Vogelzang, Paul de Souza, Gavin Marx, Ulka Vaishampayan, Saby George, James K. Schwarz, Emmanuel S. Antonarakis, Joseph M. O'Sullivan, Arash Rezazadeh Kalebasty, Kim N. Chi, Robert Dreicer, Thomas E. Hutson, Amylou C. Dueck, Antonia V. Bennett, Erica Dayan, Milan Mangeshkar, Jaymes Holland, Aaron L. Weitzman, Howard I. Scher European Urology DOI: 10.1016/j.eururo.2018.11.033 Copyright © 2018 The Authors Terms and Conditions

Fig. 1 CONSORT diagram. Patient disposition shown at the time of study closure. Two patients did not receive study treatment because of eligibility violations that were discovered after randomization but before initiation of study treatment. ITT=intent to treat. European Urology DOI: (10.1016/j.eururo.2018.11.033) Copyright © 2018 The Authors Terms and Conditions